Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7x19 CAR-T for Refractory/Relapsed B Cell Lymphoma
NCT03929107Phase 2Unknown
- Start
- Mar 2019
- Primary completion
- Jan 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 7x19 CAR-T in B cell lymphoma. Primary endpoints: Complete Remission Rate at 3 months and Adverse Events at 24 months. Status: unknown.
02
Drugs
7x19 CAR-T
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03929107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03929107.